HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Pediatrics · Pain Management Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Pediatrics · Pain Management Therapeutic Area Assessment

188 signals · 13 insights · 836 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 67%

Evidence

1037 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Pediatrics · Pain Management integrates 188 signals, 13 executive insights, and 836 regulatory precedents from the Humanexa intelligence graph. 2 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 29, 2026

    GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk

    GE HealthCare has issued a correction for Giraffe and Panda infant resuscitation systems due to a potential loosening of the air-oxygen blender knob shaft, which may affect oxygen delivery.

    View detail
  2. signalJun 29, 2026

    FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    The FDA has approved the Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride submitted by Lannett Co Inc.

    View detail
  3. signalJun 25, 2026

    FDA Approval for Oxycodone Hydrochloride by Novel Labs

    The FDA has granted approval for ANDA204021, a supplemental application for Oxycodone Hydrochloride by Novel Labs.

    View detail
  4. signalJul 24, 2026

    BioMarin's Study on Growth in Children with Idiopathic Short Stature Underway

    BioMarin Pharmaceutical is conducting a study to collect baseline growth data in children with idiopathic short stature.

    View detail
  5. regulatoryJul 24, 2026

    [ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

    PMDA document relevant to the signal.

    View detail
  6. regulatoryJul 24, 2026

    FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

    Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.

    View detail
  7. regulatoryJul 24, 2026

    FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

    Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.

    View detail
  8. regulatoryJul 24, 2026

    Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals

    Goals agreed with the Medicines and Healthcare products Regulatory Agency to clarify how their actions should support economic growth.

    View detail
  9. insightJul 12, 2026

    Haleon's Children's Advil Approval Enhances Pediatric Market Position

    The FDA's acceptance of a supplemental application for Children's Advil by Haleon is significant as it may strengthen their competitive position in the pediatric analgesic market. This development necessitates close monitoring of Haleon's marketing strategies and the approval timeline to assess potential impacts on market dynamics. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (12 high-relevance).

    View detail
  10. insightJul 2, 2026

    Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    The FDA's approval of Children's Advil-Flavored by Haleon is significant as it enhances their portfolio in pediatric pain management, a critical therapeutic area. This move could shift market dynamics, prompting competitors to reassess their strategies in the OTC space. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (5 high-relevance).

    View detail
  11. insightJun 30, 2026

    Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    View detail
  12. insightJun 30, 2026

    Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    The ongoing study on prone positioning in infants with bronchiolitis could lead to significant changes in clinical practice, particularly in pediatric intensive care. If successful, it may alter the standard of care and impact the usage of existing ventilation strategies, necessitating close monitoring by pharma strategy teams. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 13 risk-calibrated assessments for portfolio review. 836 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 8 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • [ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

    72%

    PMDA document relevant to the signal.

    Source: PMDA

    View evidence

  • FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

    72%

    Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)

    72%

    Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals

    72%

    Goals agreed with the Medicines and Healthcare products Regulatory Agency to clarify how their actions should support economic growth.

    Source: MHRA

    View evidence

  • FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)

    72%

    Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.

    Source: FDA

    View evidence

  • FDA TA — BINIMETINIB (ORIG)

    77%

    Application ANDA217678. Sponsor: ALEMBIC PHARMS LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: BINIMETINIB.

    Source: FDA

    View evidence

  • Haleon's Children's Advil Approval Enhances Pediatric Market Position

    74%

    The FDA's acceptance of a supplemental application for Children's Advil by Haleon is significant as it may strengthen their competitive position in the pediatric analgesic market. This development necessitates close monitoring of Haleon's marketing strategies and the approval timeline to assess potential impacts on market dynamics. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (12 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    60%

    The FDA's approval of Children's Advil-Flavored by Haleon is significant as it enhances their portfolio in pediatric pain management, a critical therapeutic area. This move could shift market dynamics, prompting competitors to reassess their strategies in the OTC space. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    86%

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    52%

    The ongoing study on prone positioning in infants with bronchiolitis could lead to significant changes in clinical practice, particularly in pediatric intensive care. If successful, it may alter the standard of care and impact the usage of existing ventilation strategies, necessitating close monitoring by pharma strategy teams. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Regulatory and Competitive Risks for GE HealthCare's Infant Resuscitation Systems

    50%

    The correction issued by GE HealthCare for its infant resuscitation systems poses significant safety concerns that could impact patient outcomes and regulatory compliance. This situation necessitates a thorough investigation to understand the implications for product safety and market positioning. Regulatory context from MHRA (Regulation of AI in Healthcare) supports the near-term read. Assessment grounded in 19 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    91%

    The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk

    Safety Signal

  • FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    Regulatory Approval

  • FDA Approval for Oxycodone Hydrochloride by Novel Labs

    Regulatory Approval

  • BioMarin's Study on Growth in Children with Idiopathic Short Stature Underway

    Trial Update

  • FDA Accepts Supplement Application for Celecoxib by Alembic

    Regulatory Approval

  • FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs

    Regulatory Approval

  • FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

    Regulatory Approval

  • FDA Grants Approval for Novitium's Tramadol Hydrochloride

    Regulatory Approval

Insights

  • Haleon's Children's Advil Approval Enhances Pediatric Market Position

    Pediatrics · Analgesic

  • Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    Pediatrics · Pain Management

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    Pain Management · OTC

  • Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    Pediatrics · Respiratory Disease

  • Regulatory and Competitive Risks for GE HealthCare's Infant Resuscitation Systems

    Pediatrics · Medical Devices

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    Pain Management · Opioid

  • Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    Pain Management · Opioid

  • Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    Pain Management · Opioid

Companies

  • Hikma

    31 signals

  • Teva

    25 signals

  • Aurobindo Pharma

    29 signals

  • Sun Pharma

    24 signals

  • Novitium Pharma

    16 signals

  • Alembic Pharmaceuticals

    15 signals

  • Sciegen Pharmaceuticals

    15 signals

  • Strides Pharma

    12 signals

Assets

  • Levorphanol Tartrate
  • Levorphanol Tartrate
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.